New combo therapy shows promise for tough liver cancer cases
NCT ID NCT04945720
First seen Feb 28, 2026 · Last updated Apr 25, 2026 · Updated 8 times
Summary
This study tested a combination of an immunotherapy drug (durvalumab) and chemotherapy delivered directly to the liver in 30 people with advanced liver cancer that had spread into the main portal vein. The goal was to see if this approach could help patients live longer and control the cancer. The treatment is not a cure, but aims to manage the disease and improve survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Department of Minimally Invasive and Interventional Radiology, Liver Cancer Study and Service Group, Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 500060, China
Conditions
Explore the condition pages connected to this study.